tbuckley/cabot-search huggingface dataset:
POS1362 NEUROSARCOIDOSIS. STUDY OF 30 PATIENTS FROM A SERIES OF 384 SYSTEMIC SARCOIDOSIS FROM A TERTIARY UNIVERSITY HOSPITAL
Authors: A. Herrero-Morant, L. Sanchez-Bilbao, I. González-Mazón, D. Martínez-López, J. L. Martín-Varillas, R. Fernández-Ramón, M. Á. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2021)

Background: Neurosarcoidosis is a serious and infrequent complication of sarcoidosis. Data on Biologic Therapy (BT) efficacy is scarce. Objectives: To assess in neurosarcoidosis a) its prevalence and associations of clinical clusters and b) efficacy and safety of BT. Methods: Study of neurosarcoidosis from a large cohort (n=384) of all consecutive patients diagnosed with sarcoidosis from January 1, 1999 to December 31, 2019 in a single University hospital. Results: 30 (19 women/ 11 men) out of 384 (7.8%) patients had neurosarcoidosis. Mean age at diagnosis was 41.8±15.8 years. Clusters of clinical associations were lungs (n=23, 76.7%) and joints (n=15, 50.0%) (Figure 1). The underlying neurological manifestations were chronic headache (n=13, 43.4%), peripheral neuropathy (n=6, 20.0%), cranial neuropathy (n=5, 16.7%), spinal cord abnormalities (n=3, 10.0%) and aseptic meningitis (n=3, 10.0%). 26 (86.7%) patients received oral corticosteroids (mean maximum dose 50±19.2mg) and 7 (23.3%) iv corticosteroids. In addition, 18 (60.0%) patients received conventional immunosuppressants and 12 (40.0%) BT. 4 (13.3%) did not have any treatment. Table 1 shows the main clinical features and treatment. Figure 1. Clusters of clinical associations in neurosarcoidosis 12 patients received treatment with 14 BT. Monoclonal anti-TNFα (n=10, 83.3%) was the most used BT. 10 (83.3%) patients treated with BT achieved clinical remission. No serious adverse effects were observed. Conclusion: Neurosarcoidosis was observed in 7.8% of systemic sarcoidosis. Most patients treated with BT, especially monoclonal anti-TNFα, achieved clinical remission. Table 1. Main clinical features and treatment of 30 patients with neurosarcoidosis. n (% ) Conventional immunosuppressant, n (% ) monoclonal anti-TNFα, n (% ) Etarnecept, n (% ) Tocilizu-mab, n (% ) Secukinu-mab, n (% ) Rituxi-mab, n (% ) Chronic headache 13 (43.4) 5 (38.5) 2 (15.4) 0 (0) 0 1 (7.7) 1 (7.7) Peripheral neuropathy 6 (20.0) 4 (66.7) 3 (50.0) 1 (16.7) 0 0 0 Cranial neuropathy 5 (16.7) 4 (80.0) 3 (60.0) 0 0 0 0 Spinal cord abnormalities 3 (10.0) 1 (33.3) 1 (33.3) 0 0 0 0 Aseptic meningitis 3 (10.0) 2 (66.7) 2 (66.7) 0 1 (33.3) 0 0 Disclosure of Interests: Alba Herrero-Morant: None declared, Lara Sanchez-Bilbao: None declared, Iñigo González-Mazón: None declared, David Martínez-López: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Lilly, Janssen, and Celgene, Raúl Fernández-Ramón: None declared, Miguel Á. González-Gay Speakers bureau: AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene and MSD, Grant/research support from: AbbVie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Sanofi, Lilly and MSD, Grant/research support from: AbbVie, MSD, and Roche
All‐in‐One DNA Extraction Tube for Facilitated Real‐Time Detection of Infectious Pathogens
Authors: Younseong Song, Yong Tae Kim, Yunho Choi, Hogi Kim, Min Hee Yeom, Yesol Kim, Tae Jae Lee, Kyoung G. Lee, Sung Gap Im
Journal: Advanced Healthcare Materials (2021)

An "all-in-one tube" platform is developed, where the genetic analysis involving DNA extraction, amplification, and detection can be performed in a single tube. The all-in-one tube consists of a polymerase chain reaction (PCR) tube in which the inner surface is conformally modified with a tertiary-amine-containing polymer to generate a strong electrostatic interaction with DNA. The all-in-one tube provides high DNA capture efficiency exceeding 80% from Escherichia coli O157: H7 pathogen at a wide range of DNA amount from 0.003 to 3 ng. Indeed, the use of the surface-functionalized PCR tube enables direct amplification and detection of the surface-captured DNA without the modification of standard real-time PCR instrument. Besides, this platform has sensitivity, selectivity, and reliability enough for accurate detection at the minimal infective dose of both gram-positive and negative pathogens. The all-in-one tube enables the direct molecular diagnosis, substantially reducing the labor-intensive pathogen detection steps while providing high compatibility with the currently established real-time PCR instruments, and illustrates its on-site applicability with convenience expandable to various genetic analyses including food safety testing, forensic analysis, and clinical diagnosis.
POS0673 TOLEROGENIC DENDRITIC CELLS IN RHEUMATOID ARTHRITIS PATIENTS: NEWS AND PROMISES
Authors: Y. Kurochkina, E. Chernykh, A. Sizikov
Journal: Annals of the Rheumatic Diseases (2021)

Background: Dendritic cells (DCs) are known to contribute to the pathogenesis of rheumatoid arthritis (RA) through presentation of cartilage glycoprotein, production of proinflammatory cytokines and activation of Th1/Th17 responses. Along with stimulating activity, DCs may exhibit suppressive functions via capacity to induce T cell apoptosis/anergy and to generate regulatory T cells. Since these DCs have potential to control autoreactive T-lymphocytes, the enhancing of tolerogenic properties of DCs seems to be a new important strategy in treatment of RA. Dexamethasone is widely used in clinical practice and can be used as a tolerogenic substance. Therefore, the properties of DCs generated in presence of dexamethasone are of great clinical interests. Objectives: The aim of our study is to describe the properties of tolerogenic DCs, generated with dexamethasone in patients with RA and their influence on autologous T-cells. Methods: Sixty five patients with RA with high and moderate activity of disease were recruited in this study. All patients follow ACR/EULAR criteria (2010). All studies were performed after receiving informed consent. All patients received conventional synthetic DMARDs. DCs were generated from blood monocytes culturing for 5 days with GM-CSF and IFN-α in the presence dexamethasone (dexDCS), applied on third day. LPS as maturation stimuli was added on fourth day. The expression of CD14, CD83, HLA-DR, TLR-2 on the surface of DCs was measured by flow cytometry. The functions of DCs were evaluated by measuring cytokine production and DCs allostimulatory activity in mixed lymphocyte culture. Mature DCs generated in absence of dexamethasone used as control. Results: We revealed that dexDCs are characterized by enhanced expression of CD14+cells and decreased number of CD83+cells but percent of HLA-DR+cells were constant (about 85). DexDCs show high expression of TLR-2 is seen as tolerogenic molecule (75%vs51%, p=0.05 compared to control). DexDCs also have marked prominent increase of TNFα/IL-10 ratio in contrast to control (0.59 vs 1.8, p=0.03). DexDCs suppressed proliferation of allogenic T-cells (2005 vs 7980 cpm, p=0.0002). To assess the stability of the DC in the proinfflamatory micro-environment after assessing stimulatory activity dexDCs were then cultivated with LPS and allostimulatory activity were evaluated one more. The stimulation activity dexDCs after incubation with LPS were not increase (4692 vs 6053 cpm, p=0.7). Also earlier we showed possibility of dexDCs induse apoptosis of autologous T-cells, activation of CD4+IL10+Tr1 and possession of antigen-specific suppression. Conclusion: The data obtained indicate that dexDCs from RA patients have the main tolerogenic features and stable in inflammatory environment that proves their potential in the treatment of rheumatoid arthritis. Disclosure of Interests: None declared
Dapagliflozin—Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?
Authors: Derek S. Chew, Daniel B. Mark
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity
Authors: Antonio Sacco, Cinzia Federico, Katia Todoerti, Bachisio Ziccheddu, Valentina Palermo, Arianna Giacomini, Cosetta Ravelli, Federica Maccarinelli, Giada Bianchi, Angelo Belotti, Rossella Ribolla, Vanessa Favasuli, Alexey S. Revenko, A. Robert Macleod, Brandon Willis, Hongbo Cai, Joana Hauser, Claire Rooney, Sophie E. Willis, Philip Lloyd Martin, Anna Staniszewska, Helen Ambrose, Lyndsey Hanson, Chiara Cattaneo, Alessandra Tucci, Giuseppe Rossi, Roberto Ronca, Antonino Neri, Stefania Mitola, Niccolò Bolli, Marco Presta, Michele Moschetta, Sarah Ross, Aldo M. Roccaro
Journal: Blood (2021)
POS0570 ASSOCIATION OF BODY FAT MASS AND ITS DISTRIBUTION WITH DISEASE ACTIVITY, PAIN AND DISABILITY IN RHEUMATOID ARTHRITIS
Authors: O. Lamkhanat, H. Azzouzi, I. Linda
Journal: Annals of the Rheumatic Diseases (2021)

Background: Rheumatoid arthritis (RA) and body composition are closely related. Recent studies have found a significant association between fat mass and disease activity and disability in RA [1]. Objectives: We aimed to study the association between body fat mass and its distribution with disease activity, disability, and pain in RA patients. Methods: This is a cross-sectional study of patients with RA diagnosis according to ACR-EULAR 2010 classification recruited from first January 2021. Those with prior cancer, hyperparathyroidism, hyperthyroidism, diabetes, chronic kidney disease, and cirrhosis were excluded. Body fat mass (BFM) and its distribution (gynoid (GFM), android (AFM), visceral (VFM), limbs (LFM), trunk (TFM)) were measured with dual-energy X-ray absorptiometry (Hologic, Horizon QDR®). Clinical data and laboratory tests of the same day of the DXA scan were analyzed. The associations between BFM and its distribution with disease activity score (DAS28CRP), pain visual analogue scale (VAS), and disability measured by health assessment questionnaire (HAQ) were explored. Obesity was defined as a body mass index (BMI) ≥ of 25kg/m 2 . Our statistical analysis was based on descriptive study, comparisons and linear regressions using SPSS 20. Results: It is about 69 RA patients. Their mean age was 49.86 ± 14.33 years, mean DAS28CRP was 2.56 ± 1.27, and mean disease duration was 14.84 ± 10.99 years. Sixty-two (89.9%) were women. The mean BMI was 26.46 ± 5.26 kg/m 2 , and 41 patients were obese (59.4%). Compared with non-obese patients, obese patients had a higher C-reactive protein (p = 0.03). DAS28CRP was higher in obese patients (2.77 ± 1.41 vs 2.25 ± 0.97) but did not reach significance (p = 0.07). We did not find any difference between the two groups regarding pain and disability. In univariate regression analysis, the LFM was positively associated with disease activity (p = 0.001; β = 0.38), pain (p = 0.001; β = 0.38) and disability (p = 0.007; β = 0.32). Adjusted on BMI, LDL cholesterol, triglyceride, cumulative dose of corticosteroid, disease and corticosteroid duration, menopause duration, dose and duration of methotrexate, we found a significant association between LFM, disability (p = 0.02; β = 0.51), disease activity (p = 0.02; β = 0.54) and pain (p = 0.009; β = 0.57). However, we had no association between disease activity, pain, and disability with BFM and the other components. Conclusion: Limbs fat mass was significantly associated with the activity, disability, and pain in RA patients. References: [1]Kyeong Min Son, Seong Hun Kang, Young Il Seo, Hyun Ah Kim. Association of body composition with disease activity and disability in rheumatoid arthritis. Korean J Intern Med. 2021 Jan;36(1):214-222. Disclosure of Interests: None declared
A vital sign-based prediction algorithm for differentiating COVID-19 versus seasonal influenza in hospitalized patients
Authors: Naveena Yanamala, Nanda H. Krishna, Quincy A. Hathaway, Aditya Radhakrishnan, Srinidhi Sunkara, Heenaben Patel, Peter Farjo, Brijesh Patel, Partho P. Sengupta
Journal: npj Digital Medicine (2021)

Abstract Patients with influenza and SARS-CoV2/Coronavirus disease 2019 (COVID-19) infections have a different clinical course and outcomes. We developed and validated a supervised machine learning pipeline to distinguish the two viral infections using the available vital signs and demographic dataset from the first hospital/emergency room encounters of 3883 patients who had confirmed diagnoses of influenza A/B, COVID-19 or negative laboratory test results. The models were able to achieve an area under the receiver operating characteristic curve (ROC AUC) of at least 97% using our multiclass classifier. The predictive models were externally validated on 15,697 encounters in 3125 patients available on TrinetX database that contains patient-level data from different healthcare organizations. The influenza vs COVID-19-positive model had an AUC of 98.8%, and 92.8% on the internal and external test sets, respectively. Our study illustrates the potentials of machine-learning models for accurately distinguishing the two viral infections. The code is made available at https://github.com/ynaveena/COVID-19-vs-Influenza and may have utility as a frontline diagnostic tool to aid healthcare workers in triaging patients once the two viral infections start cocirculating in the communities.
POS1283 SPONDILODISCITIS WITHOUT DOCUMENTED GERM: WHAT THERAPEUTIC MANAGEMENT?
Authors: R. Grassa, N. El Amri, K. Baccouche, S. Lataoui, H. Zeglaoui, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2021)

Background: Spondylodiscitis (SD) is an infectious inflammation that affects the vertebrae, vertebral discs and adjacent structures. It may have a bacterial or non-bacterial etiology. Although analysis has improved and identification of pathogens is highly pursued, in one third of cases, no organism can be identified. Objectives: The objective of our work is to describe the epidemiological, clinical and evolutionary profile of SD with no germ identified and management. Methods: This is a retrospective study including 37 cases of SD with no germ identified, collected in the Rheumatology Department of Farhat Hached hospital in Sousse, Tunisia over a period of 22 years (1998-2020). Results: The mean age was 59.7 years [18-97 years]. These were 21 men (56.76 %) and 16 women (43.24 %).Spinal pain was the major symptom. The lumbar location was the most frequent in 56.76% of cases. It was a multifocal localization in 21.62%. The imaging allowed the detection of para abscesses -vertebral in 43.24%. An epiduritis was objectified in 54.05%.CT-guided biopsy was performed in 59.46% and it was not conclusive. A bacteriological survey was carried out and came back negative. Spondylodiscitis was presumed to be tubercular and staphylococcal in respectively 62.16 % and 18.92 %. The tuberculosis origin was retained in view of the chronic evolution, the multi-stage damage in the radiological assessment. While staphylococcal SD was retained due to the presence of cutaneous lesion and subacute evolution. Large-spectrum antibiotic therapy was initiated in the other cases.One case was initially considered to be staphylococcal but with epidural and soft tissue extension tuberculosis was then considered to be the cause. The evolution after initiation of adequate antibiotic treatment was interspersed with neurological complications in one case of tuberculosis SD. Conclusion: Our results show a higher frequency of presumed tuberculosis SD considering the endemicity of our country and the improvement under anti tuberculosis treatment. References: [1]Cornett, C. A., and al. Bacterial Spine Infections in Adults. Journal of the American Academy of Orthopaedic Surgeons, 24(1), 11–18.(2016) [2]Lener, S., and al Management of spinal infection: a review of the literature. Acta Neurochirurgica, 160(3), 487–496.(2018) [3]Homagk, L., and al SponDT (Spondylodiscitis Diagnosis and Treatment): spondylodiscitis scoring system. Journal of Orthopaedic Surgery and Research, 14(1).(2019) Disclosure of Interests: None declared
A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays
Authors: Adam Penn-Nicholson, Sivaramakrishnan N. Gomathi, Cesar Ugarte-Gil, Abyot Meaza, Evelyn Lavu, Pranav Patel, Bandana Choudhury, Camilla Rodrigues, Sarabjit Chadha, Mubin Kazi, Aurélien Macé, Pamela Nabeta, Catharina Boehme, Raman R. Gangakhedkar, Sanjay Sarin, Ephrem Tesfaye, Eduardo Gotuzzo, Philipp du Cros, Srikanth Tripathy, Morten Ruhwald, Manjula Singh, Claudia M. Denkinger, Samuel G. Schumacher
Journal: European Respiratory Journal (2021)

Background Bringing reliable and accurate tuberculosis (TB) diagnosis closer to patients is a key priority for global TB control. Molbio Diagnostics have developed the Truenat point-of-care molecular assays for detection of TB and rifampicin (RIF) resistance. Methods We conducted a prospective multicentre diagnostic accuracy study at 19 primary healthcare centres and seven reference laboratories in Peru, India, Ethiopia and Papua New Guinea to estimate the diagnostic accuracy of the point-of-care Truenat MTB, MTB Plus and MTB-RIF Dx assays for pulmonary TB using culture and phenotypic drug susceptibility testing as the reference standard, compared with Xpert MTB/RIF or Ultra. Results Of 1807 enrolled participants with TB signs/symptoms, 24% were culture-positive for Mycobacterium tuberculosis , of which 15% were RIF-resistant. In microscopy centres, the pooled sensitivity of Truenat MTB and Truenat MTB Plus was 73% (95% CI 67–78%) and 80% (95% CI 75–84%), respectively. Among smear-negative specimens, sensitivities were 36% (95% CI 27–47%) and 47% (95% CI 37–58%), respectively. Sensitivity of Truenat MTB-RIF was 84% (95% CI 62–95%). Truenat assays showed high specificity. Head-to-head comparison in the central reference laboratories suggested that the Truenat assays have similar performance to Xpert MTB/RIF. Conclusion We found the performance of Molbio's Truenat MTB, MTB Plus and MTB-RIF Dx assays to be comparable to that of the Xpert MTB/RIF assay. Performing the Truenat tests in primary healthcare centres with very limited infrastructure was feasible. These data supported the development of a World Health Organization policy recommendation of the Molbio assays.
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia
Authors: Hassan Awada, Arda Durmaz, Carmelo Gurnari, Ashwin Kishtagari, Manja Meggendorfer, Cassandra M. Kerr, Teodora Kuzmanovic, Jibran Durrani, Jacob Shreve, Yasunobu Nagata, Tomas Radivoyevitch, Anjali S. Advani, Farhad Ravandi, Hetty E. Carraway, Aziz Nazha, Claudia Haferlach, Yogen Saunthararajah, Jacob Scott, Valeria Visconte, Hagop Kantarjian, Tapan Kadia, Mikkael A. Sekeres, Torsten Haferlach, Jaroslaw P. Maciejewski
Journal: Blood (2021)
AB0217 NON MEDICAL SWITCH FROM ETANERCEPT ORIGINATOR TO BIOSIMILAR GP2015 IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES
Authors: M. Colaci, M. L. Aprile, A. La Rosa, A. DI Maggio, L. Malatino
Journal: Annals of the Rheumatic Diseases (2021)

Background: In the last decades, new biologic drugs were introduced for the treatment of chronic inflammatory arthropathies, progressively leading to a relevant increase of medical costs. However, the introduction of biosimilars (biologic molecules similar to branded drugs with expired patent) permitted to optimize the financial resources. The non-medical switch (NMS) is the switch from a biologic originator to a biosimilar agent for economic reasons only, on the basis of the substantial equivalence as regards efficacy and safety between originator and biosimilar drugs. In literature, several evidences from clinical trials and registry studies showed that the switch from etanercept originator to biosimilar SB4 was safe [1]. Instead no sufficient data may be found regarding the biosimilar GP2015. Objectives: We aimed to evaluate efficacy, safety, and retention rate in a series of patients with chronic arthritis treated with etanercept originator who underwent to NMS towards the ETN biosimilar GP2015. Methods: From March to June 2020, all patient referred in our Centre affected by rheumatoid arthritis (RA), psoriatic arthritis (PA) and axial spondyloarthritis (axSpA) treated with etanercept originator and in remission/low disease activity for at least 6 months underwent to NMS. Data on disease activity (DAS28-PCR/CDAI/SDAI; DAPSA; BASDAI), eventual adverse events and causes of withdrawal of therapy were collected at 2, 4 and 6 months after the switch. Results: We recruited 71 consecutive patients (M/F: 24/47; mean age 55,8± 11,1 years; 39 RA; 15 PA; 17 axSpA; mean duration therapy 7.3±3.8 years). Disease activity was unchanged for almost all patients after 6 months from the switch (median ΔDAS28-PCR/CDAI/SDAI: 0,1/0/0,5; median ΔDAPSA: 0; median ΔBASDAI: 0) Moreover, the 6-month retention rate was 97.2%. Only 2 patients (2.8%) switched back to the originator due to loss of efficacy in one case and adverse events in the second case (paraesthesia, headache, dizziness and worsening of arthralgia). Conclusion: Our study confirmed that the NMS from ETN originator to GP2015 represents a safe practice that maintains the efficacy of the current treatment. References: [1]Glintborg B, AG, Omerovic E, et Al . To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis 2019; 78 :192–200. Disclosure of Interests: None declared
Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection
Authors: Deeksha Munnur, Qiwen Teo, Denzel Eggermont, Horace H. Y. Lee, Fabien Thery, Julian Ho, Sophie Wilhelmina van Leur, Wilson W. S. Ng, Lewis Y. L. Siu, Antje Beling, Hidde Ploegh, Adan Pinto-Fernandez, Andreas Damianou, Benedikt Kessler, Francis Impens, Chris Ka Pun Mok, Sumana Sanyal
Journal: Nature Immunology (2021)